
Loading, please wait...

Loading, please wait...

A prospective randomized trial compared femtosecond laser-assisted cataract surgery (FLACS) with conventional phacoemulsification over 12 months. Four hundred patients were randomized, with outcomes including unaided visual acuity, refraction, corneal thickness, endothelial cell loss, adverse events, and patient-reported quality of life. At 12 months, mean unaided distance visual acuity was essentially comparable between FLACS and conventional surgery, with no significant difference between groups. The study therefore did not show a clinically important long-term visual advantage for FLACS in routine cataract surgery. The findings are relevant when counseling patients about what femtosecond assistance can and cannot be expected to add beyond modern phacoemulsification. For surgeons, the evidence supports a selective rather than automatic approach to adopting FLACS, especially when cost, operating-room workflow, and case complexity are considered. FLACS can still have technical advantages, including automated capsulotomy and lens fragmentation, but these should be balanced against the absence of a clear 12-month superiority signal in routine cases. The study reinforces the importance of matching technology to the individual cataract, surgical goals, and available resources rather than assuming that greater automation necessarily produces better final vision.

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


A prospective randomized trial compared femtosecond laser-assisted cataract surgery (FLACS) with conventional phacoemulsification over 12 months. Four hundred patients were randomized, with outcomes including unaided visual acuity, refraction, corneal thickness, endothelial cell loss, adverse events, and patient-reported quality of life. At 12 months, mean unaided distance visual acuity was essentially comparable between FLACS and conventional surgery, with no significant difference between groups. The study therefore did not show a clinically important long-term visual advantage for FLACS in routine cataract surgery. The findings are relevant when counseling patients about what femtosecond assistance can and cannot be expected to add beyond modern phacoemulsification. For surgeons, the evidence supports a selective rather than automatic approach to adopting FLACS, especially when cost, operating-room workflow, and case complexity are considered. FLACS can still have technical advantages, including automated capsulotomy and lens fragmentation, but these should be balanced against the absence of a clear 12-month superiority signal in routine cases. The study reinforces the importance of matching technology to the individual cataract, surgical goals, and available resources rather than assuming that greater automation necessarily produces better final vision.
Today

The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back

A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back

Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back

A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back

A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back